were included. Demographic, surgical, and pathologic variables were compared, and factors associated with survival were determined via multivariate analysis. Results. The number of patients increased annually in the FMUUH cohort but not in the MSKCC cohort. Patients at MSKCC were slightly older (mean age 83.7 vs. 82.7 years), more commonly female (38 vs. 19%), and had higher average body mass index (BMI; 26 vs. 23). Treatment at FMUUH more frequently employed total gastrectomy (59 vs. 20%) and laparoscopic surgery (65 vs. 7%), and less frequently included adjuvant therapy (11 vs. 18%). In addition, FMUUH patients had larger tumors of more advanced T, N, and TNM stage. Morbidity (35 vs. 25%, p = 0.08) and 30-day mortality (2.5 vs. 3.3%, p = 0.67) were similar between the cohorts. For each TNM stage, there was no significant difference between MSKCC and FMUUH patients in 5-year overall survival and disease-specific survival (DSS). TNM stage was the only independent predictor of DSS for both cohorts. Conclusions. Patients C 80 years of age selected for gastrectomy for GC at MSKCC and FMUUH had acceptable morbidity and mortality, and DSS was primarily dependent on TNM stage.
Gastric cancer (GC) is the fifth most common malignancy worldwide, with nearly one million new cases every year. 1 The global distribution of GC varies across regions, with the highest disease burden in East Asia. The disease continues to carry a poor prognosis, accounting for over 700,000 deaths per year.
1,2 GC most frequently develops at approximately 60-65 years of age. Because life expectancy in the US has now reached 80 years of age, and more than 75 years in China, 3, 4 and the proportion of elderly in both populations is predicted to grow, the incidence of GC will likely increase.
Previous studies on elderly GC patients defined elderly patients as 70 years of age or older. 5, 6 According to an analysis of the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, these patients accounted for nearly 30% of GC patients in the period 2004-2010. 7 Patients aged 70 years or older make up a similar proportion of GC patients in China. 8 However, few reports have described outcomes following surgery in GC patients aged C 80 years. In addition, there is controversy regarding whether treatment strategies for elderly patients with GC should differ from those for younger patients.
Recently, several studies have compared GC patients in the East and West, 9-11 but none focused on elderly patients. Little is known about how tumor features, therapeutic strategies, and prognosis for these patients compare between Eastern and Western countries. In this study, we analyzed data from two institutions [Memorial Sloan Kettering Cancer Center (MSKCC) in the US and Fujian Medical University Union Hospital (FMUUH) in China] on patients age C 80 years with GC who underwent R0 resection.
METHODS

Patient Selection
We queried prospectively maintained GC databases at MSKCC and FMUUH for patients who underwent curative-intent resection between 2000 and 2013. Inclusion criteria were defined as (1) age C 80 years; (2) histologically confirmed primary gastric adenocarcinoma; (3) no distant metastasis; and (4) radical gastrectomy with R0 resection and regional lymphadenectomy. In the MSKCC cohort, five patients with R1 resection and two patients with R2 resection were excluded, and the R0 resection rate was 95.8%. In the FMUUH cohort, three patients with R1 resection and one patient with R2 resection were excluded, and the R0 resection rate was 96.7%. Exclusion criteria were (1) intraoperative evidence of peritoneal dissemination or distant metastasis; (2) incomplete histopathological or survival data; (3) gastric remnant carcinoma; and (4) wedge resection or endoscopic mucosal or submucosal resection. Patients were evaluated for fitness for surgery by the primary surgeon, and all patients had preoperative anesthesia evaluation. There was liberal use of preoperative cardiology, geriatrics, and other subspecialty evaluations as needed. 12 Institutional Review Board approval was obtained from MSKCC and FMUUH.
Patient Characteristics
We compared the following patient characteristics between the MSKCC and FMUUH cohorts: age, sex, body mass index (BMI), and ethnicity. For the FMUUH cohort, the Charlson Comorbidity Index (CCI) score, 13 and Eastern Cooperative Oncology Group (ECOG) performance status 14 were available. We also compared treatment characteristics, including type of operation, extent of lymphadenectomy, surgical approach (minimally invasive or open), use of neoadjuvant therapy, postoperative morbidity and mortality, and use of adjuvant chemotherapy and/or radiation. Pathological characteristics compared between the groups included tumor size, location, differentiation, lymph node (LN) retrieval, and stage. Tumor stage was determined according to the 8th edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) classification system. 15 Follow-up after R0 resection generally consisted of clinic visits, with laboratory and computed tomography (CT) scans repeated every 3-6 months for 2 years and every 6-12 months for years [3] [4] [5] . Disease status at last follow-up was based on a retrospective review of medical records, review of the Social Security Death Index in the US, and data from the Department of Gastric Surgery or National Statistical Office in China. Perioperative chemotherapy for patients with advanced GC generally consisted of a combination of a fluoropyrimidine and a platinum agent.
Endpoints and Statistical Analysis
The primary endpoints of the study were diseasespecific survival (DSS) and overall survival (OS), which were calculated at 5 years and stratified according to TNM stage. DSS was defined as time from resection to death from GC recurrence and/or metastasis, while OS was defined as time from resection to death from any cause.
Data are presented as means ± standard deviations for continuous variables, and medians for discrete variables. Differences were evaluated using Student's t test (continuous variables) and the Chi square test (proportions). Pearson's correlation coefficient (r) was used to assess the relationship between the number of patients older than 80 years of age and year of surgery. DSS and OS were estimated using the Kaplan-Meier method. The difference in survival distributions was evaluated by log-rank test, and the relationship between survival and clinical risk factors was evaluated by Cox regression. A P value of 0.05 was considered statistically significant. All analyses were performed in SPSS (IBM Corporation, Armonk, NY, USA).
RESULTS
Patient Demographics and Treatment Characteristics
A total of 159 MSKCC patients and 118 FMUUH patients who met the inclusion criteria were identified, representing 9.8% of the 1627 patients at MSKCC and 2.9% of the 4071 patients at FMUUH undergoing gastrectomy for GC during the 14-year time period. While there was no time trend in the number of elderly patients treated with surgery at MSKCC (electronic supplementary Fig. 1a) , this number increased linearly over time at FMUUH (r = 0.685, p \ 0.001) (electronic supplementary Fig. 1b ). Patients at MSKCC were, on average, older than those at FMUUH (83.7 ± 3.3 vs. 82.7 ± 2.8, p = 0.006), and FMUUH patients were more frequently male (81.4 vs. 61.6%, p \ 0.001) ( Table 1) . Mean BMI was higher in patients treated at MSKCC (26.1 ± 3.8 vs. 22.5 ± 3.1 kg/ m 2 , p \ 0.001). All patients treated at FMUUH were Asian, whereas 79.9% of patients treated at MSKCC were Caucasian, 9.4% were Black, 8.8% were Asian, and 1.9% were another ethnicity. For FMUUH patients, 73% had an ECOG performance status of 0-1 and 27% had an ECOG performance status of 2-3. The CCI was 0 for 42% of these patients, 1-2 for 38%, and C 3 for 20%. We did not have ECOG and CCI data on MSKCC patients.
Patients treated at MSKCC were more likely to undergo distal gastrectomy than patients treated at FMUUH (65.4% vs. 38.1%, p \ 0.001) ( Table 1) . A higher proportion of FMUUH patients underwent minimally invasive surgery (65.3% vs. 6.9%, p \ 0.001), and a lower proportion received neoadjuvant therapy compared with MSKCC patients (1.6% vs. 10.7%, p \ 0.05). A similar proportion of patients received postoperative adjuvant therapy at each of the two centers (10.1% and 10.2%, p [ 0.05).
Pathologic Characteristics
Among patients at FMUUH, tumors were larger (5.4 ± 2.8 vs. 4.3 ± 2.9 cm, p = 0.004), were more frequently located in the upper third of the stomach (29.7 vs. (Fig. 1) . Although the OS curves were not significantly different, MSKCC patients had better DSS than patients at FMUUH (p \ 0.05) (Fig. 1a) centers when stratified by stage. In addition, morbidity (25-35%) and mortality (2.5-3.4%) at both institutions were reasonable, and AJCC tumor stage was the most significant independent predictor of survival. Elderly cancer patients have decreased functional reserves and are thus more likely to experience morbidity than younger patients. [16] [17] [18] However, two Korean studies have found similar morbidity and mortality between elderly (defined as C 70 or C 75 years) and younger patients with GC. 19, 20 Although 30-day mortality in the current study (2.5-3.4%) was slightly higher than that in previous reports on patients of all ages (2% at MSKCC 10 and 0.4% at FMUUH 21 ) and a multi-institutional study in Japan, 22 it was similar to that reported by some European institutions (2.1-5.5%). [23] [24] [25] Moreover, the 90-day mortality rate in this study was also similar or less than the previously studies (5.8-13.7%).
26-28 Thus, we conclude that the postoperative mortality of surgery is acceptable in elderly patients whose disease has not metastasized and who are healthy enough to undergo operation with acceptable postoperative mortality.
Previous comparisons of GC outcomes between Asian countries and the US have found that survival is better among patients treated in Korea and Japan, 9,29 but not in China. 30 Indeed, in the present study, Chinese patients had more advanced cancer and more LN metastases than U.S. patients. Screening for GC by upper gastrointestinal endoscopy is not widespread in China, and Chinese patients with cancer, especially those in rural areas, are often reluctant to seek treatment. 31 Another potential reason for the greater survival of GC patients in Korea and Japan is the lower frequency of cancers affecting the upper third of the stomach, 9,29 which are associated with worse outcomes. 32 In contrast, we observed similar proportions of GC patients with tumors affecting the upper third between institutions in the US and China, confirming a previous report by Strong et al. 30 Moreover, there were similar noncurative resection (R1/R2) rates between the MSKCC and FMUUH cohorts (4.2 vs. 3.3%), which were slightly lower than that in a previous report on patients of all ages (9.7% in MSKCC), 33 which may partly contribute by more careful selection of early clinical stages for elderly patients to surgery.
In this study, significant differences in tumor characteristics and treatment were observed between the cohorts. Patients at MSKCC were older on average, included a higher proportion of women, and had a higher average BMI, consistent with previous studies comparing GC in Eastern and Western populations. In addition, only two patients (1.7%) at FMUUH received preoperative chemotherapy, which is significantly fewer than at MSKCC (10.7%) but consistent with differing standards of practice between the US and China. 10 Although elderly patients generally have more comorbidities and worse health status than younger patients, their DSS and prognostic factors following gastrectomy for GC appear similar. Previous comparisons of elderly and nonelderly GC patients found similar DSS between the two groups, 34 with no effect of age on survival. 35 The 5-year DSS rate that we observed for the MSKCC cohort (58.3%) is similar to previous reports on GC patients of all ages. 10, 30 Similarly, the 5-year DSS rates for each stage were similar to those in a recent evaluation of the 7th edition revisions to AJCC staging. 36 These comparable DSS rates were observed in spite of much less frequent use of neoadjuvant chemotherapy than that for younger patients. Although there was significantly better DSS in the MSKCC cohort compared with the FMUUH cohort, there was no significant difference between cohorts with the same stage cancers, and TNM stage was the only independent predictor of DSS in both cohorts. Since a relatively high proportion of elderly patients die of other causes within a 5-year interval of their major gastric surgery, OS could be used as a complementary and important outcome measure for elderly GC patients. In the current study, OS was also not significant different between the two cohorts when stratified by stage.
The benefit of surgery in elderly patients with late-stage GC is controversial. In the current study, the proportion of patient deaths due to other diseases was higher among early-stage patients (electronic supplementary Table 1 ) as the majority of these patients are cured by surgery. However, for patients with later-stage disease, 5-year DSS is much lower, around 20% for stage III in our study. A recent investigation found that surgery provided benefit to patients aged 85-89 years, but not patients aged 90 years or older; 37 however, age may not be the key factor. An editorial on that study suggested that comorbidities were the key reason for differing outcomes, and that chronological age alone is not sufficient reason to withhold surgical treatment. 38 There are several limitations to this study. First, its retrospective and nonrandomized nature makes it subject to selection bias. We were not able to compare all patients at least 80 years of age who had operable GC because their data could not be reliably obtained from the databases of our institutions. There were certainly patients who did not undergo surgical resection, despite having resectable disease, because they were medically unfit. Second, there were some discrepancies between the two institutional databases, which may confound the differences in demographic and tumor characteristics between the cohorts. Third, this study is limited by a relatively small sample size. Fourth, we did not have additional data on quality of life, nutritional status, immune function, medication absorption status, and other measures that could be major considerations when evaluating these elderly patients for radical resection. Despite these limitations, this study provides insight into the outcomes of patients aged 80 years or older following radical gastrectomy and could be used as a basis for future prospective studies. Our findings suggest that aggressive surgical treatment may be effective in these elderly patients.
CONCLUSIONS
We found several differences in demographics, treatment standards, and pathological findings between patients aged 80 years and older undergoing surgical resection for GC at a high-volume cancer center in the US and those treated at a similar institution in China. However, stagespecific 5-year OS and DSS did not differ significantly between the two cohorts, and tumor stage was the only independent risk factor for DSS. When relevant selection guidelines are followed, surgery can be performed in these patients with acceptable morbidity and mortality.
